Today we interview Dr. Ghulam Rehman Mohyuddin of Kansas University Medical Center on his new paper out now in The Lancet Haematology titled "Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review".

Control Groups: doi.org/10.1016/S2352-3026(21)00024-7

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

March 2021

3.56 Quality of Control Groups in RCTs of Multiple Myeloma with Dr. Ghulam Rehman Mohyuddin

Today we sit down with Dr. Kirsten Bibbins-Domingo, Chair of the Department of Epidemiology and Biostatistics and the inaugural Vice Dean for Population Health and Health Equity in the UCSF School of Medicine. We talk about mentorship throughout a career, the unique value of epidemiology and biostatistics, finding passion in your work, disparities in healthcare during the COVID-19 pandemic, and more.

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

May 2021

3.71 How Research Influences Policy with Dr. Kirsten Bibbins-Domingo

On today's episode, we interview Dr. Marty Makary of Johns Hopkins School of Medicine and Bloomberg School of Public Health on how he chose his path in medicine, how health care as it is in the United States needs to change, and how groupthink dominated COVID-19 health policy. We discuss a variety of topics from his research on overuse, the prevalence of burnout in healthcare professionals, silos in medicine, to patients' lawsuits against hospitals. We touch on his two books, the latter of which has a new edition coming out next month that addresses COVID-19: Unaccountable: What Hospitals Won't Tell You and How Transparency Can Revolutionize Health Care, and "The Price We Pay: What Broke American Health Care--and How to Fix It".

Unaccountable: https://www.bloomsbury.com/us/unaccountable-9781608198368/
The Price We Pay: https://www.bloomsbury.com/us/the-price-we-pay-9781635575910/

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

June 2021

3.90 Redesigning Health Care, Overuse, Burnout, and COVID-19 Groupthink with Dr. Marty Makary

Today we interview Dr. Bita Fakhri of UCSF on the current research behind treatments for lymphoma. We touch on CAR-T, ABVD, DA-EPOCH-R, and more. We also talk about histiocytic disorders, Dr. Fakhri's career in academia, and learning through teaching.

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

August 2021

4.16 Treating Lymphoma, Histiocytic Disorders, Learning by Teaching, & More! with Dr. Bita Fakhri

We have two oncology conversations for you today. The first is with Dr. Saroj Niraula of the University of Manitoba, and together we discuss the necessity of randomized controlled trials for granting FDA approval of cancer drugs. The second is with Dr. Ghulam Rehman "Manni" Mohyuddin of the University of Utah on a variety of myeloma studies, including LIGHTHOUSE, OCEANS, and HORIZON.

Feasibility of RCTs: doi.org/10.1093/jncics/pkab061
RR of Alternative Treatments: doi.org/10.1002/ijc.33231
Study Time Reduction: doi.org/10.1001/jamainternmed.2018.8351

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

4.17 RCTs for Cancer Drug Approval with Dr. Saroj Niraula & Myeloma Studies with Dr. Manni Mohyuddin

Today we're joined by social epidemiologist, Dr. Maria Glymour of UCSF. We talk about her work in studying public health interventions for dementia and how her experience in academia has led to her conviction in the necessity of rigorous, quantitative technical skills training for epidemiology PhD students. We touch on how to have a good idea, her advice for PhD applicants, and working in a soft money (grants) vs hard money environment. Finally, we discuss her idea for a stepped-wedge trial approach to evaluate the new Alzheimer's drug, aducanumab. 

Aducanumab: https://sites.bu.edu/melodem/files/2021/07/Pragmatic-Study-Designs-to-Accelerate-Aducanumab-Evidence_Glymour.pdf

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

4.18 Dementia Interventions, Skills for Epidemiologists, & Aducanumab with Dr. Maria Glymour

This week we take a break from #zercovid to give you another episode that's a deep dive into COVID-19. We start with an interview with epidemiologist and infectious disease expert Dr. Daniel Morgan of the University of Maryland School of Medicine; we talk about cognitive errors in medical decision-making and how it relates to COVID-19 health policy. After that, we have a series of thoughts for you on COVID vaccine mandates for schools, President Biden's vaccine plan, the FDA's vote on boosters, John Ioannidis' new paper on vaccinating students, the Pfizer results for vaccines in kids 5-11, and accepting that COVID is here to stay.

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

September 2021

4.21 Cognitive Errors in Medical Decision-Making with Dr. Daniel Morgan & COVID-19 Policy

On today's episode, in honor of him and in recognition of his passing, we have an old interview with Dr. Elihu Estey of the University of Washington on his 40 years of experience as an oncologist, the "Renaissance" of drugs for leukemia, and advice for trainees on how to approach career goals. This interview originally aired as episode 1.49. He will be missed.

October 2021

4.22 Honoring Dr. Elilhu Estey and His Decades-Long Oncology Career

I get back to my roots; I explain surrogate validation and a new JCO paper from the FDA authors on EFS and OS in AML. You won't want to miss it

4.60 - NEW JCO paper - AML, EFS, CR, CRi, and Surrogate validation - FDA & Methods

Zeb joins me for the 7th time to discuss all the key pandemic questions

Zeb Jamrozik - Vaccine errors/ Sweden/ Equipoise & Science itself

Simultaneously released on Sensible Medicine. Time to subscribe to Sensible Medicine substack and podcast.

Prasad and Mandrola discuss recent journal articles/ Republicans/ Stenting

Screening/ Drug efficacy/ Sotorasib/ Adaura and more

How We Can Do Better As A County Hospital

AI in healthcare - my latest keynote address

Artificial Intelligence in Medicine - My Keynote

Lecture on systematic review, given by Vinay Prasad MD MPH to students in the UCSF Training in Clinical Research Program, November 2024.

Systematic Reviews - An Introduction⧸ How to do them⧸ Search Strategies⧸ Common Errors

Our 2 hour critical appraisal and ASH review.  
SO many guest stars

2 HOUR ASH Presentation with AARON GOODMAN & MANNI & More

Is alcohol healthy for you? I break down everything you need to know about beer, wine, and spirits.

Alcohol - Is it healthy? Everything you need to know about Beer, Wine and Spirits

The entire healthcare system is broken, it's not just health insurance companies.

The ENTIRE healthcare system is broken, not just health insurance companies

I discuss Trump's big health care changes: NIH study sections, the MMWR gag order, the US withdrawal from WHO, and more!

Trump's Big Health Care Changes: NIH study sections, MMWR gag order, WHO withdrawal & more!

I discuss the CIA admitting that COVID was a lab leak; Fauci's pardon; NIH meetings; RFK Jr's Senate confirmation hearing; and more.

CIA says lab leak, Fauci's pardon, NIH's meetings, RFK Jr's hearing & more!

I discuss the recent reduction in indirect funds for NIH grants and lay out why the NIH is a broken funding system.

Why the NIH is a broken funding system

I'm talking about USAID and Elon's team of six engineers; the Bobby Kennedy Jr hearings, particularly concerning Samoa; MMR vaccines; DEI; and NIH funding complaints.

Elon's 6 Engineers/ Unelected/ RFK Jr/ MMR vaccines/ DEI/ USAID and NIH funding complaints

I discuss the intense media coverage of Trump and the recent decision to cap indirect costs of NIH grants at 15%.

Trump is breaking media brains / NIH cuts indirect payments and scientists freak out

I discuss RFK Jr.'s confirmation as the US Secretary of Health and Human Services; recent layoffs at the CDC and NIH; and some comments by Harold Varmus in criticism of Jay Bhattacharya. 

RFK Jr takes office/ CDC layoffs/ Varmus criticizes Jay's proposal for Academic Freedom

CABINET - trial - Cabozantinib for NET

In the first half of this episode, Dr. Sven Olson of OHSU joins us to help critique the recent NEJM paper, "Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura". In the second half, we interview Dr. Inmaculada Hernández of the University of Pittsburgh on her work on the economic principles behind runaway drug prices.

Caplacizumab: doi.org/10.1056/NEJMoa1806311

Back us on Patreon! www.patreon.com/plenarysession

February 2019

1.42 Caplacizumab for TTP with Dr. Sven Olson & Economics of Drug Pricing with Dr. Inma Hernández

We're back with more questions of the week! Our first question, from Ian Straehley, is inspired by the USMLE Step 2 CK; our second question, from Audrey Tran, is on deciding on a medical specialty. We end the episode with an interview with Dr. Frank Harrell of Vanderbilt University on the Bayesian approach to statistical thinking.

Back us on Patreon! www.patreon.com/plenarysession

August 2019

2.06 Heart Failure, Choosing a Specialty, & the Bayesian Approach with Dr. Frank Harrell

On this week's BONUS episode, we sit down with Dr. Huseyin Naci, Assistant Professor of Health Policy at the London School of Economics, to discuss his new paper that came out Wednesday (producer's edit: not "yesterday" as said in the podcast - apologies for the delay!) in the British Medical Journal. The paper's titled "Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis."

RCTS Supporting Approvals: doi.org/10.1136/bmj.l5221

Back us on Patreon! patreon.com/plenarysession

September 2019

2.13 BONUS! RCTs Supporting Approvals of Cancer Drugs by EMA with Dr. Huseyin Naci

This week we start with an in-depth monologue on various new developments surrounding COVID-19, specifically the new study in NEJM on the compassionate use of remdesivir as well as the CDC's advice for the general public to wear cloth masks. We end with an interview with Dr. Ameet Sarpatwari of Harvard Medical School on how to create a more effective pharmaceutical system, the CREATES Act of 2019, developing fair and equitable drugs to treat COVID-19, and how to create a just system that balances the need for innovation with the need for access. Dr. Ameet Sarpatwari is the Assistant Director of PORTAL.

Compassionate Use of Remdesivir: doi.org/10.1056/NEJMoa2007016
U.S. Gene Therapy Trials: doi.org/10.1001/jama.2019.22214
NIH Fair Pricing Condition: doi.org/10.7326/M19-2576

Back us on Patreon! www.patreon.com/plenarysession

April 2020

2.47 Remdesivir, Cloth Masks, & Incentives for COVID-19 Drug Development with Dr. Ameet Sarpatwari

This BONUS lecture was a talk given to the Hematology/Oncology fellows at Oregon Health & Science University. It's part three of a three-part series on clinical trials. 

Back us on Patreon! www.patreon.com/plenarysession

May 2020

2.51 BONUS! Clinical Trials Part 3

This week we have an announcement -- the audiobook of "Malignant: How Bad Policy and Bad Evidence Harm People with Cancer", written and narrated by our host Vinay Prasad, is available now on Amazon, iTunes, and Audible!
We also have an in-depth journal club for you on the findings of the PROfound trial as published in a new paper out in the New England Journal of Medicine titled "Olaparib for Metastatic Castration-Resistant Prostate Cancer". 
Finally, we end the episode with an interview with Dr. Adam Cifu of the University of Chicago on literature, medicine, maintaining a feeling of normalcy and self during COVID-19, and more! 

Listen to Malignant with a free 30-day trial of Audible: https://www.audible.com/pd/B08864KFHW/?source_code=AUDFPWS0223189MWT-BK-ACX0-195112&ref=acx_bty_BK_ACX0_195112_rh_us

PROfound: doi.org/10.1056/NEJMoa1911440
Crossover: doi.org/10.1093/annonc/mdy116

Back us on Patreon! www.patreon.com/plenarysession

2.52 Malignant Audiobook, PROfound trial, & Literature and Medicine with Dr. Adam Cifu

This week's episode is jam-packed with topics! We talk about the RECOVERY trial, the U.S. clinical trial infrastructure, event-free survival (EFS) and cost of care in acute myeloid leukemia, how long it takes to write papers in academic medicine, threats to public health officials, and the application to medicine of Dr. Raj Chetty's work in economics. Finally, we interview this week's special guest, Dr. Ian Tannock, on docetaxel, prostrate cancer, clinical trial appraisal, and his career in medicine.

RECOVERY: https://www.recoverytrial.net/
EFS in AML: doi.org/10.1182/bloodadvances.2019001150

Malignant audiobook: https://www.audible.com/pd/B08864KFHW/?source_code=AUDFPWS0223189MWT-BK-ACX0-195112&ref=acx_bty_BK_ACX0_195112_rh_us

Back us on Patreon! www.patreon.com/plenarysession

June 2020

2.57 RECOVERY, Clinical Trials in the US, EFS, Writing, Dr. Raj Chetty, & Dr. Ian Tannock

This week we have two fantastic interviews for you: The first is with Dr. Ben Mazer on the interplay between social media and news; the second is with Dr. Tem Bendapudi on whether Caplacizumab should be the standard of care for thrombotic thrombocytopenic purpura (TTP).

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

October 2020

3.18 Social Media and News with Dr. Benjamin Mazer & Caplacizumab for TTP with Dr. Tem Bendapudi

Dr Prasad currently serves as the Director of the Center for Biologics Evaluation and Resesarch (CBER) at the US FDA. The audio on this platform were posted before my FDA employment and do not necessarily represent the views of the FDA or the United States. This site will be inactive during my federal service.

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

Plenary Session - inactive due to federal service

Popular tracks